Rhinomed (RNO, 17.5 cents)Market capitalisation: $44 millionThree-year total return: +4.1% a yearAnalysts’ consensus valuation: n/a The Melbourne-based Rhinomed is a specialist in respiratory airway technology: it is a world-leading developer of nasal devices made from ultra-soft medical-grade bio-compatible polymers, that helps the volume of air travelling through the nose. The company has brought to market three kinds of…
Company Info: Adherium (ADR, 2.5 cents)Market capitalisation: $17 millionThree-year total return: -33.8% a yearAnalysts’ consensus target price: n/a Adherium is a global leader in medication compliance technology, developing devices that monitor the extent to which patients suffering chronic illness take their medications as prescribed. More than 50% of such patients do not do so, resulting…
One of the stocks most hammered by the COVID correction in February-March was Qantas, which plummeted from $6.67 to $2.14, a fall of 68%, as the effect of the pandemic on air travel began to sink-in to the market. Like most of its peers, Qantas found itself in “the most challenging period in its long…
The forgotten precious metal – silver – is quietly having a blinder of a year. With a 34.7% gain so far, silver is outperforming gold, the S&P 500, the Dow Jones Industrial Average, the DAX Index in Germany, and the Nikkei index in Tokyo. At US$24.27 an ounce, silver is up 63.3% since March, but…
And still they keep coming – here’s the fifth instalment of our series on the fascinating ASX cohort of medical device developers. As always, don’t let the impressive sexiness of the technology persuade you on its own that these stocks are headed for the stars. In each of the three cases presented here, previous investors…
Four years ago, old high-school buddies Nicholas Quinn and Jesse Moors were taking in the sunshine at a café on Melbourne’s Southbank, when they decided to take their mutual interest in stock market investment to the next level. Quinn, a former PwC global tax specialist, and Moors, formerly a business development manager at CPA Australia,…
OK, so you want to own a big global diversified bulk miner, to take advantage of the impending commodities boom – let’s take a look at the contenders, BHP and Rio Tinto. Here’s the tale of the tape. BHP (BHP, $36.35)Market capitalisation: $183.7 billionOne-year total return: +6.9%Three-year total return: +17.9% a yearFive-year total return: +14.2%…
One of the great investment success stories of the last 25 years has been the exchange-traded fund (ETF), which got under way in the early 1990s as a vehicle offering access, in one listed stock, to the entire stock market through tracking an index. Gone were the worries of paying “active” management fees and failing…
Here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. ImpediMed (IPD, 8.1 cents)Market capitalisation: $83.8 millionThree-year total return: -52.7% a yearAnalysts’ consensus target price: 14 cents (Thomson Reuters) You would not know it from the share price performance over the last few years, but Brisbane-based ImpediMed has put…
With the deleveraging plans out in the marketplace, analysts think there is more value in the European/North American angle when it comes to the Westfield story, with consensus target prices for Unibail-Rodamco-Westfield on the ASX showing far greater expected upside than for the Scentre Group’s Australian-New Zealand exposure. So much so that there have…
